What is the Optimal Design-Build-Test Cycle for Clinically Relevant Synthetic CAR T Cell Therapies?

Yvonne Y. Chen; Wendell Lim; Megan Levings; Bruce Blazar; Giedre Krenciute; Wilson Wong; Manfred Lehner

doi:10.1016/j.cels.2020.08.017

What is the Optimal Design-Build-Test Cycle for Clinically Relevant Synthetic CAR T Cell Therapies?

Yvonne Y. Chen
, Wendell Lim
, Megan Levings
, Bruce Blazar
, Giedre Krenciute
, Wilson Wong
, Manfred Lehner

Health Sciences Administration

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	212-214
Number of pages	3
Journal	Cell Systems
Volume	11
Issue number	3
DOIs	https://doi.org/10.1016/j.cels.2020.08.017
State	Published - Sep 23 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.cels.2020.08.017

Find It

Find It at U of M Libraries

Cite this

@article{d3b96d7ed3804088a0a8dcab0540cf13,

title = "What is the Optimal Design-Build-Test Cycle for Clinically Relevant Synthetic CAR T Cell Therapies?",

author = "Chen, \{Yvonne Y.\} and Wendell Lim and Megan Levings and Bruce Blazar and Giedre Krenciute and Wilson Wong and Manfred Lehner",

year = "2020",

month = sep,

day = "23",

doi = "10.1016/j.cels.2020.08.017",

language = "English (US)",

volume = "11",

pages = "212--214",

journal = "Cell Systems",

issn = "2405-4712",